Afimoxifene (4-hydroxytamoxifen or (E/Z)-4-hydroxy Tamoxifen), an active metabolite of tamoxifen with both estrogenic and anti-estrogenic effects, is a SERM (selective estrogen receptor modulator). Afimoxifene is a mixture of the configurational isomers of 4-hydroxytamoxifen: (Z)-4-Hydroxytamoxifen and (E)-4-Hydroxytamoxifen isomers. Afimoxifene is a transdermal gel formulation and is being developed by Ascend Therapeutics, Inc. under the trademark TamoGel. Afimoxifene has completed a phase II clinical trial for the treatment of cyclical mastalgia. A study in France on 55 women showed that rubbing afimoxifene on the skin was as good as tamoxifen tablets at slowing breast cancer growth. A US trial will compare 6 weeks use before breast cancer surgery. Skin application can reduce systemic levels by a factor of nine and this is expected to reduce the unpleasant side-effects of tamoxifen.

纯度：≥98%

CAS：68392-35-8